All In Biotech

Drug Trial Radar · NCT06650007

the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

A Multicenter, Randomized, Double-blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Nov 8, 2024

Primary completion

Jan 21, 2026

Study completion Jun 12, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effectiveness of HRS9531 compared to placebo in controlling blood glucose levels after 36 weeks of treatment

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • HRS9531 InjectionDrug

    HRS9531 Injection

  • HRS9531 Placebo InjectionDrug

    HRS9531 Placebo Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: from baseline to 36 weeks treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.